OM:XVIVOMedical Equipment
Assessing Xvivo Perfusion (OM:XVIVO) Valuation After PRESERVE Trial Success And Strong Q1 Profit Turnaround
Xvivo Perfusion (OM:XVIVO) has drawn fresh attention after reporting Q1 2026 results alongside preliminary PRESERVE Trial data, which met pre set safety and efficacy endpoints for extended criteria donor heart preservation and transport.
See our latest analysis for Xvivo Perfusion.
The share price momentum has been strong, with a 65.65% year to date share price return and a 44.93% 30 day share price return, even though the 1 year total shareholder return is slightly negative. This suggests...